Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys - Wikidata - awgldk - TriplyDB

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

http://www.wikidata.org/entity/Q41880655

about

Fc glycans of therapeutic antibodies as critical quality attributes Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.Assessments of antibody biodistribution.Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.Antibody-dependent fragmentation is a newly identified mechanism of cell killing in vivo.Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.Improved assembly of bispecific antibodies from knob and hole half-antibodies.Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding.A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus.IgG Fc engineering to modulate antibody effector functions.Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants.Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death.Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus.

P2860

Q26799266-F8CF5EF5-5013-46A3-8B49-C735FE3AD178 Q31091923-D32FCD99-8A9B-431A-A398-9492C65FC99F Q34884133-5110C780-CB17-4610-BFB6-DA1410DF6659 Q35152029-3EDDA87F-1770-43AD-9149-3FF25B63DABF Q35866472-2D9B8A30-827D-4D6C-9916-78F5C252DFD6 Q37598513-31A9993B-5C7C-42E9-90E6-2E23D53C2705 Q38364460-3C90A1A4-B6A6-4E1E-BC5C-AE666F69E147 Q38725387-B38E7C33-3721-4A4E-ADD6-33843D83FA66 Q38748910-D1F482E3-8BEA-453A-8BC7-75E5AA548E85 Q41620299-03A91C7E-D5E9-4230-B788-5F0BB3048C41 Q42390676-C8A5928F-81E3-4049-B560-FB793D23E3AA Q42584647-1BE4135E-FB1B-4BA0-B9DA-D9CC01EB54D4 Q46330101-1DE7A98A-1BA1-488E-AE35-6DC2D22EBD43 Q46711768-D01CABDD-F448-44C6-9825-49DE8DE3C187 Q47147171-6F69EB6A-F326-4E2F-9500-E1003F372A7E Q47156413-ECEDD83A-B1B4-47D8-BC4B-739AEF234283 Q47593242-A06D3AD5-D1F5-4E0F-9EA8-1C0BBA55435E Q48662932-BCAEC92C-FBEA-4BA2-986F-C0B6E9AAEE8E Q50048248-0E4B8E8B-88A8-4AB8-A441-BA7C8D53DF60 Q55177411-C2F25C01-E879-4C2C-A3AD-F472FC699365 Q55338916-4879E3AC-1B3F-4057-BEBA-782B5350D318

P2860

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

http://www.wikidata.org/entity/Q41880655

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

@en

type

label

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

@en

prefLabel

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

@en

P1433

Q41880655-0582BE69-CB17-4C7A-9759-90464C4F539C

P1476

Q41880655-4AB96D61-934D-41DA-A137-A9D53168763F

P2093

Q41880655-0BDBE6C4-6A87-496E-97DD-30AD892FE756

Q41880655-5DE65AFA-AC4D-4696-B0D6-1BC94A859F39

Q41880655-5E70EFA0-53E8-4B55-A4BA-9EFB60D57601

Q41880655-7E02375D-8FC9-461C-950D-C121F42AE5D7

Q41880655-C135E483-802D-407D-934A-5F03A05292F7

Q41880655-D577B94A-BBBA-40A2-9429-D0D5C0E5A8F2

P2860

Q41880655-02B9641F-8AA7-4E0C-83F6-471B59502DD5

Q41880655-0548DE72-E07B-468F-8B94-86267AD803C6

Q41880655-0B5CFF0B-7638-4F19-B44F-C15991D5A245

Q41880655-0EDA9FDE-9A5C-4612-BB84-BD7EB5ABFB0E

Q41880655-13168CDB-3216-424E-B212-3FBC0EA7ED8A

Q41880655-16057703-5894-4E54-8DE4-3DF9A87C31E3

Q41880655-17DBC096-41A3-46F5-9403-D7A260D2D7D7

Q41880655-26905AFA-E3B7-4462-B718-B4418468CCAF

Q41880655-29CA5412-55F1-476B-B664-E5D229B8B156

Q41880655-2BF10C1B-E4C8-440B-A9CB-6B6EF436D828

P304

Q41880655-8C13D4F8-D500-4ACF-9E99-0CF384EFA1DC

P31

Q41880655-3929A5D0-CAAF-457E-BE74-F8DE649B22F1

P356

Q41880655-66A65B6E-D1B9-4520-8971-782704C3CEF2

P433

Q41880655-7BAC7907-0D2A-4871-BAEC-4D641136863B

P478

Q41880655-991D0B57-FC79-433F-8FF5-D560DF760E93

P577

Q41880655-93343D5A-FBC7-49CB-9AEE-9DF7EFEA1AF5

P5875

Q41880655-E646FD52-DEA6-4537-AAB7-93F9FE7C0D60

P698

Q41880655-BA9476AA-DBC2-4881-BB7F-FD0FB9B473EB

P932

Q41880655-705F0312-9EAE-4789-A707-36B914CF8B96

P356

P1433

Monoclonal Antibodies

P1476

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

@en

P2093

Kyra J Cowan

http://www.w3.org/2001/XMLSchema#string

Laura E DeForge

http://www.w3.org/2001/XMLSchema#string

Maya K Leabman

http://www.w3.org/2001/XMLSchema#string

Robert F Kelley

http://www.w3.org/2001/XMLSchema#string

Suhasini Iyer

http://www.w3.org/2001/XMLSchema#string

Y Gloria Meng

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

Fcgamma receptors as regulators of immune responses

Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

The covalent structure of an entire gammaG immunoglobulin molecule.

Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes.

Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.

Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.

The impact of glycosylation on the biological function and structure of human immunoglobulins.

P304

896-903

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.26436

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260090108

http://www.w3.org/2001/XMLSchema#string

P698

24492343

http://www.w3.org/2001/XMLSchema#string

P932

3896603

http://www.w3.org/2001/XMLSchema#string